Definium Therapeutics (NASDAQ:DFTX) Releases Earnings Results, Misses Expectations By $0.23 EPS

Definium Therapeutics (NASDAQ:DFTX) posted its quarterly earnings data on Thursday. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23), FiscalAI reports.

Here are the key takeaways from Definium Therapeutics’ conference call:

• Three pivotal DT120 ODT phase III readouts are imminent — EMERGE (MDD) top-line later this quarter, and VOYAGE and PANORAMA (both GAD) expected in early and late Q3 respectively, with Breakthrough Therapy designation for DT120 in GAD and an NDA submission planned subject to positive data.
• All pivotal trials are near complete (EMERGE 149 enrolled; VOYAGE 214; PANORAMA >200) and were powered around a 5‑point placebo‑adjusted difference (VOYAGE/PANORAMA >99% power; EMERGE 80% with ~3‑point significance threshold), which management says targets clinically meaningful and durable single‑dose effects.
• Each study includes a Part B with up to one year of follow‑up and up to four open‑label retreatments triggered at moderate symptoms, intended to characterize retreatment patterns, durability, and longer‑term safety for potential labeling discussions.
• The company ended Q1 with $373.4 million in cash and investments, which management believes provides runway to fund planned operations through multiple pivotal readouts and into 2028.
• Near‑term spend ramped materially — Q1 R&D rose to $41.5M and G&A to $17.7M versus prior year — contributing to a wider net loss of $77.1M, with a $20M quarterly impact from warrant fair‑value movement, indicating higher cash burn and elevated execution costs ahead.

Definium Therapeutics Price Performance

Shares of NASDAQ DFTX traded down $1.15 during trading on Friday, hitting $22.05. The company had a trading volume of 2,203,452 shares, compared to its average volume of 1,963,772. The company has a market cap of $2.20 billion, a P/E ratio of -8.86 and a beta of 2.37. Definium Therapeutics has a 52 week low of $6.03 and a 52 week high of $26.25. The business’s 50-day moving average is $19.98 and its 200 day moving average is $16.05. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.29 and a current ratio of 6.29.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on DFTX. Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 price target on shares of Definium Therapeutics in a research note on Thursday, April 23rd. Royal Bank Of Canada boosted their target price on Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Stifel Nicolaus set a $30.00 price target on Definium Therapeutics and gave the company a “buy” rating in a research note on Thursday, April 16th. Leerink Partners boosted their price objective on Definium Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Definium Therapeutics in a research note on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Definium Therapeutics currently has a consensus rating of “Buy” and an average target price of $37.92.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Commodore Capital LP boosted its stake in Definium Therapeutics by 10.5% in the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after purchasing an additional 475,000 shares during the period. Orbimed Advisors LLC acquired a new position in Definium Therapeutics in the 3rd quarter worth approximately $4,337,000. Two Sigma Investments LP boosted its position in shares of Definium Therapeutics by 424.9% in the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock worth $3,495,000 after buying an additional 239,965 shares during the period. Vanguard Group Inc. grew its holdings in shares of Definium Therapeutics by 11.0% during the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after buying an additional 198,878 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Definium Therapeutics by 62.6% during the third quarter. Millennium Management LLC now owns 298,205 shares of the company’s stock valued at $3,516,000 after buying an additional 114,805 shares in the last quarter. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.